Invivyd, Inc.

NASDAQ:IVVD

Biotechnology

Healthcare
$0.47 +4.16%

+$0.04 today

Market cap
$138.68M
Beta
0.63
P/E (TTM)
-3.9
EPS (TTM)
-$0.25
52W Low $0.48High $3.07

Volume 6.71M

Average 3.62M

IVVD Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Invivyd, Inc.NASDAQ: IVVD

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $30.73M rose 188.8% year over year, ahead of the -50.0% change in trailing-twelve-month research & development. Sequentially, it rose 205.8% from the prior quarter. Over 3 fiscal years it compounded at -40.2% a year.

Context

  • Research & development amounted to 71.7% of revenue in FY2025, down 469.0 pp from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +188.8% holds above the trailing-twelve-month pace of -50.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$30.73M+205.8% QoQ
Last fiscal yearDec 2025
$38.31M-72.1% YoY
LTMMar 2026
$58.4M-50.0% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+188.8%——
1 year-72.1%——
3-year CAGR-40.2%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
38.31M USD
Year-over-year change
-72.1%
4-year CAGR
-32.3%

Research & Development vs competitors

How IVVD compares with its peers on the latest reported figures

  • IVVD's LTM Mar 2026 research & development of $58.4M is the 4th highest of the 10 companies compared; the peer median is $46.96M.
  • Its year-over-year change of -50.0% is the lowest of 9, against a peer median of +19.8%.
  • Research & development amounts to 104.5% of revenue for IVVD, versus a peer median of 238.4%.
IVVD Competitors Peer median
Research & Development for IVVD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$113.23M +11.4%-23.3%327.7%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$101.77M -11.6%-4.0%291.9%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$60.48M +28.2%+38.4%184.8%
IVVDInvivyd, Inc.LTM Mar 2026$58.4M -50.0%-40.2%104.5%
CDXSCodexis, Inc.LTM Mar 2026$47.7M -0.5%-13.2%61.1%
TARAProtara Therapeutics, Inc.LTM Mar 2026$46.96M +41.8%+36.4%—
OABIOmniAb, Inc.LTM Mar 2026$44.75M -15.8%-0.4%154.8%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$23.16M +47.2%-19.1%—
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$17.59M +68.3%+29.6%902.4%
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026$3.93M ———
Peer median (excluding IVVD) $46.96M+19.8%-2.2%238.4%

Competitors are the stored peer set for IVVD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00025.38M53.43M
Cost of Revenue0001.62M3.75M
Gross Profit00023.77M49.68M
Gross Margin———93.6%93.0%
Research & Development182.89M179.21M158.66M137.25M38.31M
Selling, General & Admin36.52M47.04M49.13M63.39M66.93M
Operating Expenses226.91M248.03M212.76M200.64M105.24M
Depreciation & Amortization1K462K2.03M3.11M2.11M
EBITDA(219.41M)(225.8M)(205.76M)(166.81M)(50.38M)
EBITDA Margin———-657.2%-94.3%
Operating Income(226.91M)(248.03M)(212.76M)(176.88M)(55.56M)
Operating Margin———-696.8%-104.0%
Interest Income06.71M06.95M0
Interest Expense043.08M000
Other Income / Expenses118K6.71M14.12M6.95M3.07M
Income Before Tax(226.79M)(241.32M)(198.64M)(169.93M)(52.49M)
Pre-Tax Margin———-669.4%-98.2%
Income Tax Expense00000
Net Income(226.79M)(241.32M)(198.64M)(169.93M)(52.49M)
Net Margin———-669.4%-98.2%
EPS (Basic)(2.11)(2.17)(1.81)(1.43)(0.30)
EPS (Diluted)(2.11)(2.17)(1.81)(1.43)(0.30)
Weighted Avg Shares110.78M108.27M109.53M118.56M172.21M
Weighted Avg Shares (Diluted)110.78M108.27M109.53M118.56M172.21M

Invivyd, Inc.

NASDAQ:IVVD

Intrinsic Alpha fair value

Locked

Current Price

$0.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.